Gluco Mild Ingredients

Centella grows in wet ground across South and Southeast Asia and has a long kitchen and medicine-cabinet history in both. What reached the clinic is narrower than the plant: the venous studies used a titrated total triterpenic fraction, a concentrate assayed for asiaticoside, madecassoside and asiatic acid, given at 60 mg twice daily for eight weeks.

That material carried a placebo-controlled trial in venous hypertensive microangiopathy, a companion study built on a combined microcirculatory model, a long-haul flight study of ankle swelling and a study in diabetic microangiopathy. A dose-ranging arm compared 30 mg and 60 mg three times daily and the larger amount did more. The systematic review that pooled eight of these trials calls the direction consistent and the quality modest, and points out that most of the work comes from one group of investigators.

The plant part matters here more than anywhere else on this list. NCCIH states that the raw seeds, bark, flowers and leaves of horse chestnut are unsafe taken by mouth because they contain a toxic component. The material used in the trials is a processed seed extract assayed for aescin, with the esculin taken out, and that processing is the whole difference between a studied supplement and a poisonous conker.

What that processed extract did is unusually concrete. A 1996 Lancet comparison set it against compression stockings and against placebo over twelve weeks at 50 mg of aescin twice daily, and the extract and the stockings reduced lower-leg volume by a similar amount. The Cochrane review of seventeen trials found reductions in leg pain, oedema, itching and calf circumference; a meta-analysis of thirteen trials and large observational series reached the same conclusion; and an earlier placebo-controlled oedema study and a criteria-based review sit underneath both. This artwork names the plant without naming the part or the assay, so a reader is trusting the maker on the point the research turns on.

A spiny Mediterranean shrub whose rhizome has been used for heavy legs for a very long time, and whose modern file has an awkward shape. Most of the evidence belongs to Cyclo 3 Fort, a capsule of Ruscus extract 150 mg with hesperidin methyl chalcone 150 mg and ascorbic acid 100 mg, so the result is a property of the combination rather than of the root on its own.

A meta-analysis covering 10,246 subjects found reductions in leg pain, heaviness and oedema, and a European Venous Forum symposium report went back over the graded evidence for it. The cleanest single-ingredient result is a twelve-week placebo-controlled trial of a Ruscus preparation alone, which reported reduced leg volume. Worth knowing alongside that: a case report proposed the same vein-tightening action as a way of treating orthostatic hypotension, so this is a compound with a measurable effect on vessels generally and not only on the ones that ache.

Hawthorn berry is the most cardiological plant in this bottle and almost all of its clinical record belongs to one German preparation, WS 1442, standardised to oligomeric procyanidins. A sixteen-week comparison ran 900 mg and 1,800 mg a day against placebo in chronic heart failure: the larger arm improved maximal exercise workload and the smaller one did not. The Cochrane review pooled fourteen trials and found benefit on exercise tolerance and symptoms when it was added to standard treatment.

The later picture is more sober and belongs here rather than in a footnote. A two-year trial in 2,681 patients missed its primary cardiac endpoint, and a 2018 benefit-risk review reads the file as favourable on symptoms and neutral on hard outcomes. A crossover trial in prehypertensive adults looked at flow-mediated dilation. Two interaction findings travel with the plant: a controlled study with digoxin found no clinically meaningful change in digoxin levels, while a meta-analysis of the hawthorn and camphor combination found that particular pairing raises blood pressure by design. NCCIH’s page is the short version.

The most recently studied plant of the seven, and the one whose results are easiest to read because they are measured in millimetres of mercury. A 2019 randomised trial gave grape seed proanthocyanidin extract at 200 mg and at 400 mg a day for twelve weeks to adults with prehypertension; the 400 mg arm dropped systolic pressure by around 13 mmHg and improved endothelial function, and the 200 mg arm achieved less.

A dose-response meta-analysis pooled controlled trials of flow-mediated dilation, blood pressure and heart rate and found the effect real and related to the amount taken. A meta-analysis of sixteen randomised trials reported a modest systolic reduction and an earlier pooling of cardiovascular risk markers found the same shape. NCCIH keeps its own summary conservative. Of everything on this artwork, this is the extract that lines up most directly with a heart-health line.

A North American woodland mint whose knotty rhizome was a nineteenth-century standby for haemorrhoids and varicose veins. The entire human record in the medical literature is an 1887 note in the British Medical Journal and an 1888 note in a southern medical record. There has been no controlled study since, no dose-finding work, and no modern description of what it does in a person.

The laboratory file is short as well. A 1999 phytochemistry paper isolated a novel 2-hydroxyflavanone from the plant and a high-throughput screen included it among a long list of natural products tested against a breast carcinoma cell line. Neither describes a leg. Stone root is in this blend because herbalists have put it in this kind of blend for a century and a half, and a buyer is entitled to weigh that for exactly what it is.

A tall square-stemmed mint with a genuinely cardiotonic reputation. A review of cardiotonic plants groups Leonurus with foxglove relatives for that reason and is candid that the clinical work behind the group is thin. A review of the genus and a review of Herba Leonuri chemistry set out the alkaloids, leonurine and stachydrine among them, and the vascular effects recorded in animal and cell studies.

What is missing is a human study of the capsule-and-dropper kind. The one randomised controlled trial used a motherwort injection to reduce bleeding after an induced abortion: a different route, a different purpose and a different group of people. It is cited here because it is the honest answer to the question of what human evidence exists for this plant, and for no other reason. Motherwort also carries the reason this formula is unsuitable in pregnancy, which the side effects page sets out.